Inhibikase Therapeutics, Inc. (IKT), a pharmaceutical company, on Monday announced that it has appointed David McIntyre as Chief Financial Officer, effective from April 14.
Shares of Inhibikase Therapeutics are increasing in pre-market trading.
McIntyre has over two decades of experience and had previously worked at Anthos Therapeutics, Inc., AVITA Medical, Inc., Tessa Therapeutics, Inc.
Chief Executive Officer Mark Iwicki, "We look forward to leveraging his expertise as we continue to advance IkT-001 for PAH patients."
Friday, Inhibikase Therapeutics had closed 12.08% higher at $2.32 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.